Monographie - Melphalan

Viimane versioon :
03/05/2024

Melphalan

Keemiline struktuur

Kaubanduslikud nimed erinevates maades

Preparaatide nimed on näitlikud ja abianete sisaldus võib erineda sõltuvalt riigist ja laborist

Alkeran	Ameerika ühendriigid, Araabia Ühendemiraadid, Austraalia, Austria, Belgia, Brasiilia, Iirimaa, Itaalia, Kanada, Kolumbia, Kreeka, Luksemburg, Malaisia, Prantsusmaa, Rootsi, Saksamaa, Suurbritannia, Sveits, Tšiili, Uus-Meremaa
Egymelan	Maroko
Eriolan	Argentiina, Ecuador
Melfalan	Argentiina, Ecuador, Hispaania, Saksamaa, Tšiili
Melfoma	Argentiina, Maroko

Viited : Melphalan

	Tüüp	Avaldamine
84	Ajaleht	Trissel LA, Martinez JF. Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 495-499.
160	Ajaleht	Pinguet F, Martel P, Rouanet P, Fabbro M, Astre C. Effect of sodium chloride concentration and temperature on melphalan stability during storage and use. Am J Hosp Pharm 1994 ; 51: 2701-2704.
169	Ajaleht	Trissel LA, Martinez JF. Physical compatibility of melphalan with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1993 ; 50: 2359-2363.
182	Ajaleht	Trissel LA, Gilbert DL, Martinez JF. Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 56-60.
244	Ajaleht	Trissel LA, Martinez JF. Compatibility of filgrastim with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1907-1913.
307	Ajaleht	Trissel LA, Martinez JF. Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1792-1799.
854	Ajaleht	Chang SY, Evans TL, Alberts DS. The stability of melphalan in the presence of chloride ion. J Pharm Pharmacol 1979 ; 31: 853-854.
905	Ajaleht	Trissel LA, Martinez JF. Screening teniposide for Y-site physical incompatibilities. Hosp Pharm 1994 ; 29: 1010-1017.
1501	Ajaleht	Beitz C, Bertsch T, Hannak D, Schrammel W, Einberger C, Wehling M. Compatibility of plastics with cytotoxic drug solutions - comparison of polyethylene with other container materials. Int J Pharm 1999 ; 185: 113-121.
1520	Labor	Etude de stabilité des médicaments en Ecoflac® B Braun 2001
2247	Ajaleht	Chan P, Heatherly K, Kupiec T.C, Trissel L.A. Compatibility of caspofungin acetate injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2008 ; 12, 3: 276-278.
3516	Plakat	Vigneron J, Zenier H, May I, Nicolas A. Stabilité du melphalan à 2 mg/ml dans le chlorure de sodium 0,9% dans des conditions pratiques d'utilisation. SFPO Congress, Mandelieu, France. 2013
3584	Labor	Melphalan (Alkéran®) - Résumé des caractéristiques du produit Aspen Pharma 2013
3786	Ajaleht	Buitrago E, Lagomarsino E; Mato G; Schaiquevich P. Stability of Melphalan Solution for Intravitreal Injection for Retinoblastoma JAMA Ophtalmology 2014 ; 132, 11: 1372-1373.
3949	Plakat	Brönnimann C, Berger-Gryllaki M, Podilsky G, Sadeghipour F. Optimisation du processus de préparation des solutions de melphalan destinées à l’administration intra-vitréenne dans le traitement du rétinoblastome et étude de leur stabilité JFSPH Congress, Bern, Switzerland. 2016
3977	Ajaleht	Desmaris R.P, Mercier L, Paci A. Stability of Melphalan in 0,9% Sodium Chloride Solutions Prepared in Polyvinyl Chloride Bags for Intravenous Injection. Drugs R D 2015 ;15:253-259.
4189	Ajaleht	Kawedia J, Ramchandran S, Liu X, Gulbis A, Titus M, Bashir Q, Qazilbash M, Champlin R, Ciur S, Stability of Captisol-enabled versus propylene glycol–based melphalan at room temperature and after refrigeration. Am J Health-Syst Pharm 2022 ;79,12: 1011-1018
4376	Ajaleht	Shi Z, Abruzzo T, Wanasathop A, Li S K. Compatibility of Melphalan in Iodinated Contrast Media. Int J Pharm Compound 2020 ;24,1:83-85
4701	Ajaleht	Singh R, Chen J, Miller T, Bergren M, Mallik R. Solution stability of Captisol-stabilized melphalan (Evomela) versus Propylene glycol-based melphalan hydrochloride injection. Pharm Dev Technol 2018 ; 23, 10: 1024-1029.

Mentions Légales